Video Center

The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Julie Gralow, MD, shares her thoughts on new drugs in development for breast cancer.

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, shares her thoughts on investigational drugs in development for breast cancer such as androgen receptor targeted therapies, immunotherapies, and checkpoint inhibitors

Published: 08 November 2016

Recent Videos: Breast

video

Julie Gralow, MD, shares her thoughts on new drugs in development for breast cancer.

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, shares her thoughts on investigational drugs in ...

video

Debu Tripathy, MD on the importance of cdk4/6 for future breast cancer treatments

Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center weighs in on how ...

video

Debu Tripathy, MD provides update on breast cancer treatment algorithms impacted by PD-L1

Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center talks on how PD-L1 ...

video

Lee Schwartzberg, MD, on how liquid biopsies can be used for breast cancer treatment strategies

Lee Schwartzberg, MD, Professor of Medicine, Chief, Division of Hematology Oncology, University of Tennessee Health Science Center, provides insights into ...

video

Julie Gralow, MD, shares perspective on the evolving development immunotherapies in breast cancer

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, shares her perspective on the evolving development ...

video

Mohammad Jahanzeb, MD, FACP on the role of CDK inhibitors and their evolving role in breast cancer

Mohammad Jahanzeb, MD, FACP, Professor of Clinical Medicine, Hematology/Oncology; Medical Director, Sylvester Comprehensive Cancer Center, discusses the role of CDK ...

video

Mohammad Jahanzeb, MD, FACP comments on rising drug costs relative to more effective therapies

Mohammad Jahanzeb, MD, FACP, Professor of Clinical Medicine, Hematology/Oncology; Medical Director, Sylvester Comprehensive Cancer Center, shares his thoughts on the ...

video

Mohammad Jahanzeb, MD, FACP talks about impact of CDK4/6 inhibition added to letrozole

Mohammad Jahanzeb, MD, FACP, Professor of Clinical Medicine, Hematology/Oncology; Medical Director, Sylvester Comprehensive Cancer Center, comments on the results of ...

video

Julie Gralow, MD, shares her thoughts on the topic of liquid biopsy in breast cancer.

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, shares her perspective on the concept of ...

video

Julie Gralow, MD, on the KRISTINE study

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, comment on the KRISTINE study of preoperative ...

video

Julie Gralow, MD, discusses the Monarch 1 study

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, comments on the Monarch 1 study of ...

video

Julie Gralow, MD, discusses the outcomes of the PALOMA-2 study presented at ASCO 2016

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, discusses the outcomes of the PALOMA-2 trial ...

video

Jasgit Sachdev, MD, on new drugs for treating patients w/ triple negative breast cancer.

Jasgit Sachdev, MD, Director, Breast & GYN Early Trials Program, HonorHealth Research Institute, shares her thoughts on new drugs in ...

video

Jasgit Sachdev, MD, on liquid biopsy as a promising technology for breast cancer treatment

Jasgit Sachdev, MD, Director, Breast & GYN Early Trials Program, HonorHealth Research Institute, shares her thoughts on liquid biopsy as ...

video

Jasgit Sachdev, MD, discusses the PALOMA-2 randomized study

Jasgit Sachdev, MD, Director, Breast & GYN Early Trials Program, HonorHealth Research Institute, shares her thoughts on the PALOMA-2 randomized ...

video

Lee S. Schwartzberg, MD, FACP on exciting studies for breast cancer investigational agents

Lee S. Schwartzberg, MD, FACP, Professor of Medicine, Division of Hematology/Oncology, University of Tennessee Health Science Center relays the pipeline’s ...

video

Lee S. Schwartzberg, MD, FACP discussing Paloma 2 study results from ASCO 2016

Lee S. Schwartzberg, MD, FACP, Professor of Medicine, Division of Hematology/Oncology, University of Tennessee Health Science Center on the results ...

video

Debu Tripathy, MD, provides perspective on the treatment of HER2+ breast cancer patients

Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, provides the big picture ...

video

Lee Schwartzberg, MD, interprets the results of the PALOMA-2 study presented at ASCO 2016

Lee Schwartzberg, MD, Professor of Medicine, Chief, Division of Hematology Oncology, University of Tennessee Health Science Center, provides his perspective ...

video

Debu Tripathy, MD on the evidence of palbociclib (Ibrance) efficacy in the PALOMA-2 trial

Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center on reaffirmation of efficacy ...

video

Debu Tripathy, MD discusses the PALOMA-2 trial outcomes in ER+/HER2- advanced breast cancer

Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center weighs in on the ...

video

Debu Tripathy, MD, on the use of hormonal therapy in the PALOMA-2 clinical study

Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center describes how hormonal therapies ...

video

Debu Tripathy, MD explains how liquid biopsy figures into breast cancer treatment

Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center relays how liquid biopsy ...

video

Debu Tripathy, MD regarding the MONARCH 1 (abemaciclib) study

Debu Tripathy, MD, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center provides an update on ...

Related Videos

video-image

Julie Brahmer, MD, discusses considerations when choosing between immunotherapy and chemotherapy

video-image

Julie Brahmer, MD, talks about the potential impact of immunotherapy in 1st line NSCLC

video-image

David Ettinger, MD, talks about impact of immunotherapy in 1st line metastatic NSCLC patients

video-image

Julie Gralow, MD, shares perspective on the evolving development immunotherapies in breast cancer

video-image

Eunice S. Wang, MD, discusses the toxicity of the CPX-351 (Vyxeos) in a phase III study

video-image

Alexander Perl, MD, on the toxicity in the phase 3 study evaluating CPX-351 (Vyxeos)

video-image

Alexander Perl, MD, on the role of immunotherapy in treating hematological malignancies

video-image

Tanios Bekaii-Saab, MD, on developing effective immunotherapies in CRC patients

video-image

Tanios Bekaii-Saab, MD, on progress in developing immunotherapies in non MSI- High CRC patients

video-image

David Gandara, MD, discusses considerations when choosing between immunotherapy and chemotherapy

video-image

David Gandara, MD, discusses the positioning of Cyramza post platinum therapy in NSCLC patients

video-image

David Gandara, MD, discusses PD-L1 expression and selecting the appropriate agent in NSCLC patients

video-image

Bert O’Neill, MD, on making immunotherapy more effective in mCRC

video-image

Barbara Burtness, MD on the Keynote-055 study in SCCHN patients

video-image

Robert A. Figlin, MD on clinical study that lead to approval of lenvatinib (Lenvima)

video-image

Laura Chow, MD interprets the overall survival benefit with Opdivo in the CheckMate-141 study

video-image

Alan Venook, MD on whether CALGB/SWOG 80405 study provides guidance on therapeutic regimen

video-image

Jennie R. Crews, MD talks about the goals of the ICLIO as developed by ACCC

video-image

Mark Levis, MD, on why the FLT3 target is important in AML

video-image

Mark Levis, MD, discusses the role of immunotherapy in treating hematological malignancies

video-image

Eunice S. Wang, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results

video-image

Value Tools at ASCO 2016: Building a Framework for Prime Time (Part 3)

video-image

David Ettinger, MD, provides practical advice related to PD-L1 testing in metastatic NSCLC patients

video-image

Tanios Bekaii-Saab, MD, on outcomes of CALGB/SWOG 80405 regarding primary site of tumor

video-image

Lee Schwartzberg, MD, interprets the results of the PALOMA-2 study presented at ASCO 2016

video-image

Lee Schwartzberg, MD, on how liquid biopsies can be used for breast cancer treatment strategies

video-image

Mark Levis, MD discusses importance of hitting the FLT3 target in AML patients with this mutation

video-image

Mark Levis, MD, discusses the role of checkpoint inhibitors in treating hematological malignancies

video-image

Julie Gralow, MD, shares her thoughts on the topic of liquid biopsy in breast cancer.

video-image

Julie Gralow, MD, shares her thoughts on new drugs in development for breast cancer.

video-image

Julie Gralow, MD, on the KRISTINE study

video-image

Julie Gralow, MD, discusses the Monarch 1 study

video-image

Julie Gralow, MD, discusses the outcomes of the PALOMA-2 study presented at ASCO 2016

video-image

Julie Brahmer, MD, provides practical advice related to PD-L1 testing in NSCLC patients

video-image

Julie Brahmer, MD, on the importance of overall cost of therapy

video-image

Julie Brahmer, MD, on the level of PD-L1 expression in selecting the appropriate agent in NSCLC

video-image

Jasgit Sachdev, MD, on new drugs for treating patients w/ triple negative breast cancer.

video-image

Jasgit Sachdev, MD, on liquid biopsy as a promising technology for breast cancer treatment

video-image

Jasgit Sachdev, MD, discusses the PALOMA-2 randomized study

video-image

Eunice S. Wang, MD, discusses the Quantum First Study

video-image

Eunice S. Wang, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Eunice S. Wang, MD, on Abstract 7008 & Crenolanib potential activity in relapsed FLT3 positive AML

video-image

Eunice S. Wang, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Eunice S. Wang, MD, discusses and provides perspective on why FLT3 is important

video-image

Eunice S. Wang, MD, on immunotherapy and its potential role in treating hematological malignancies

video-image

David Ettinger, MD, on cost of therapy when choosing agents for late stage lung cancer patients

video-image

David Ettinger, MD, on choosing between immunotherapy and chemotherapy in metastatic NSCLC patients

video-image

David Ettinger, MD, on the positioning of ramucirumab (Cyramza) for NSCLC

video-image

David Ettinger, MD, talks about levels of PD-L1 expression and agent selection

video-image

Aref Al-Kali, MD, discusses the toxicity of the CPX-351 (Vyxeos) in the phase III study

video-image

Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) phase III results in subsets

video-image

Aref Al-Kali, MD, discusses the impact of the CPX-351 (Vyxeos) phase III results on treatment

video-image

Aref Al-Kali, MD, discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Aref Al-Kali, MD, discusses the importance of specificity when selecting a FLT3 inhibitor

video-image

Aref Al-Kali, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Aref Al-Kali, MD, on immunotherapy and its potential role in treating hematological malignancies

video-image

Anthony El-Khoueiry, MD, talks results of nivolumab (Opdivo) trial in Hepatocellular Carcinoma (HCC)

video-image

Anthony El-Khoueiry, MD, discusses the pipeline of products in development for HCC

video-image

Anthony El-Khoueiry, MD, discusses management of Nexavar (Sorafenib) toxicities in HCC

video-image

Anthony El-Khoueiry, MD, discusses impact of new data on HCC Standard of care over last few years

video-image

Alexander Perl, MD discusses CPX-351 (Vyxeos) mechanism of action and why it is a promising agent

video-image

Alexander Perl, MD, discusses Abstract 7008 results and Crenolanib potential activity

video-image

Alexander Perl, MD, discusses the Quantum First Study and potential implications

video-image

Alexander Perl, MD, discusses the importance of sustained inhibition when selecting a FLT3 inhibitor

video-image

Alexander Perl, MD, discusses the potential impact of potency when selecting a FLT3 inhibitor

video-image

Alexander Perl, MD, on importance of FLT3 and provides his perspective on inhibitor differences

video-image

Alexander Perl, MD, on FLT3 inhibitors in development and importance of hitting the FLT3 target

video-image

David Gandara, MD, talks about the potential impact of immunotherapy in 1st line NSCLC

video-image

Julie Brahmer, MD, on positioning of ramucirumab (Cyramza) post-platinum therapy in NSCLC patients

video-image

Howard Hochster, MD on the reliability of MSI-High as a predictor of response to nivolumab

video-image

Howard Hochster, MD on the economic benefit seen in CALGB/SWOG 80405

video-image

Howard Hochster, MD talks progress in the development of effective non MSI-High immunotherapies

video-image

Nevena Damianov, MD on the reasoning for studying PD-L1 inhibition in advanced HCC

video-image

Nevena Damianov, MD relays which late stage clinical studies will impact in advanced HCC

video-image

Nevena Damianov, MD interprets how new advanced HCC agents will integrate into HCC treatment

video-image

Jennie R. Crews, MD relays the unique side effects being seen with long-term use of immunotherapies

video-image

Jennie R. Crews, MD, explains if there is a stopping point where immunotherapy shouldn’t be used

video-image

Jennie R. Crews, MD, looks at long-term efficacy with immunotherapies

video-image

Jennie R. Crews, MD, discusses the broad applicability and limitations with immunotherapy

video-image

Laura Chow, MD, provides the rationale for studying PD-L1 inhibitors in SCCHN

video-image

Jeffrey Weber, MD, PhD explains the importance of testing for NRAS as compared with a BRAF Biomarker

video-image

Jeffrey Weber, MD, PhD discusses the response rates and PFS for longer OS based on immunotherapies

video-image

Jeffrey Weber, MD, PhD discusses the long term side effects with immunotherapies

video-image

Jeffrey Weber, MD, PhD, discusses the efficacy of checkpoint inhibitors and immunotherapy

video-image

Jeffrey Weber, MD, PhD explains the importance of administering ipilimumab with a PD-L1 inhibitor

video-image

Jeffrey Weber, MD, PhD provides interpretation of the NEMO trial results

video-image

Tanios Bekaii-Saab, MD, on performance status when selecting mCRC, 3rd line treatment therapy

video-image

Tanios Bekaii-Saab, MD, comments on dosing regorafenib (Stivarga) in 3rd line treatment of mCRC

video-image

Tanios Bekali-Saab, MD, on utilizing regorafenib (Stivarga) and trifluridine (Lonserf)

video-image

Tanios Bekali-Saab, MD, comments on sequencing of immunotherapeutic agents in mCRC patients

video-image

Tanios Bekaii-Saab, MD on MSI-High as an mCRC response predictor to nivolumab (Opdivo)

video-image

Tanios Bekali-Saab, MD, tells us whether KRAS is a definitive biomarker in mCRC patients

video-image

Alexander Perl, MD on treatment based on the Phase III study evaluating CPX-351 (Vyxeos) versus 7+3

video-image

Eunice S. Wang, MD, discusses the importance hitting the FLT3 target

video-image

David Gandara, MD, discusses pembrolizumab vs docetaxel for previously treated NSCLC patients

video-image

Tanios Bekaii-Saab, MD on outcomes of CALGB/SWOG 80404 and potential impact

video-image

Tanios Bekaii-Saab, MD, comments on outcomes of CALGB/SWOG 80404 regarding primary site of tumor

video-image

Phil Bonomi, MD, on importance of checkpoint inhibitors in first-line NSCLC setting

video-image

Phil Bonomi, MD, talks about the evolving role of targeted agents in 2nd line NSCLC and beyond

video-image

Phil Bonomi, MD, discusses costs of new lung cancer therapies relative to duration of therapy

video-image

Mohammad Jahanzeb, MD, FACP on the role of CDK inhibitors and their evolving role in breast cancer

video-image

Mohammad Jahanzeb, MD, FACP speaks about testing for PD-L1 in the first-line NSCLC setting

video-image

Mohammad Jahanzeb, MD, FACP comments on rising drug costs relative to more effective therapies

video-image

Mohammad Jahanzeb, MD, FACP talks about impact of CDK4/6 inhibition added to letrozole

video-image

Mark Levis, MD, discusses significance of the Quantum-R study

video-image

Mark Levis, MD, on the mechanism of action for CPX-351 (Vyxeos) and why is it promising in AML

video-image

Mark Levis, MD discusses patient subsets that have the most need for new therapeutic options in AML

video-image

Mark Levis, MD, comments on attributes of Crenolanib in relapsed FLT3 positive AML

video-image

Mark Levis, MD comments on the importance of hitting multiple FLT3 components such as ITD and D-835

video-image

Mark Levis, MD, on importance of potency and selectivity for treating FLT3 positive patients

video-image

Alan Venook, MD talks about treatment strategies based on site of primary tumor in CRC patients

video-image

Alan Venook, MD, explains the biological difference between left-sided and right-sided CRC tumors

video-image

Alan Venook, MD explains the outcome of phase 3 CALGB/SWOG 80405 study

video-image

Robert Figlin, MD discusses how lenvatanib will fit into the advanced RCC treatment algorithm

video-image

Robert Figlin, MD, discusses recent progress in the treatment of renal cell cancer (RCC)

video-image

Robert Filgin MD explains the importance of cabozantinib as a tool in the RCC armamentarium

video-image

Robert Filgin MD provides an update on nivolumab (Opdivo) in RCC

video-image

Debu Tripathy, MD on the evidence of palbociclib (Ibrance) efficacy in the PALOMA-2 trial

video-image

Debu Tripathy, MD discusses the PALOMA-2 trial outcomes in ER+/HER2- advanced breast cancer

video-image

Debu Tripathy, MD, on the use of hormonal therapy in the PALOMA-2 clinical study

video-image

Debu Tripathy, MD provides update on breast cancer treatment algorithms impacted by PD-L1

video-image

Debu Tripathy, MD explains how liquid biopsy figures into breast cancer treatment

video-image

Debu Tripathy, MD regarding the MONARCH 1 (abemaciclib) study

video-image

Jeffrey A. Meyerhardt, MD explains results from the phase 3 CALGB/SWOG 80405 study

video-image

Jeffrey A. Meyerhardt, MD discusses the phase 3 CALGB/SWOG 80405 study

video-image

Jeffrey A. Meyerhardt, MD explains how OS from primary site of tumor may impact treatment

video-image

Jeffrey A. Meyerhardt, MD on the reliability of MSI-High as a predictor of response in mCRC

video-image

Jeffrey A. Meyerhardt, MD, discusses immunotherapy in MSI-Stable CRC patients

video-image

Jeffrey A. Meyerhardt, MD explains integration of Stivarga and Lonserf in later lines of treatment

video-image

Jeffrey A. Meyerhardt, MD weighs in on the economic vs efficacy outcomes in CALGB/SWOG 80405

video-image

Jeffrey A. Meyerhardt, MD, explains matching mutations and markers to therapies in CRC patients

video-image

Philip Philip, MD on Stivarga (regorafenib) dosage in 2nd line treatment of mCRC

video-image

Philip Philip, MD explains how to integrate regorafenib and trifluridine for 2nd line mCRC treatment

video-image

Philip Philip, MD on the importance of ipilimumab prior to nivolumab in mCRC patients

video-image

Philip Philip, MD on the reliability of MSI-High as a predictor of response to Opdivo in mCRC

video-image

Philip Philip, MD discusses phase 3 CALGB/SWOG 80405 study outcomes

video-image

Philip Philip, MD on what is impressing him at ASCO 2016 in CRC

video-image

Nevena Damianov, MD illustrates the promising classes and products for advanced, unresectable HCC

video-image

Nevena Damianov, MD discusses the toxicity concerns and how to manage them for sorafenib in HCC

video-image

Lee S. Schwartzberg, MD, FACP on exciting studies for breast cancer investigational agents

video-image

Lee S. Schwartzberg, MD, FACP discussing Paloma 2 study results from ASCO 2016

video-image

Laura Chow, MD tells us about products in development for SCCHN

video-image

Laura Chow, MD discusses cross trial comparisons with Keytruda and Opdivo in head and neck cancers

video-image

Laura Chow, MD discusses incorporating checkpoint inhibitors into standard of care

video-image

Laura Chow, MD discusses the role of PD-L1 testing in SCCHN

video-image

Jeffrey Weber, MD, PhD explains the long term data from Keynote-001 study in advanced melanoma

video-image

Jeffrey A. Meyerhardt, MD on PD-1 or PD-L1 treatment strategies for MSI-Stable mCRC patients

video-image

Debu Tripathy, MD, provides perspective on the treatment of HER2+ breast cancer patients

video-image

Bert O'Neil, MD discusses decision making based on toxicities factor for later lines of mCRC therapy

video-image

Barbara Burtness, MD talks about new patient treatment insights based on the Keynote-055 study

video-image

Barbara Burtness, MD explains if the Keynote-012 study confirms the benefit seen with Keytruda

video-image

Howard Hochster, MD explains outcomes from the phase 3 CALGB/SWOG 80405 study

video-image

Howard Hochster, MD on mCRC treatment changes due to primary site of tumor impact.

video-image

Howard Hochster, MD talks about predictive response therapy based on site of tumor in mCRC

video-image

Howard Hochster, MD on performance status importance in selecting treatment algorithms

video-image

Debu Tripathy, MD on the importance of cdk4/6 for future breast cancer treatments

video-image

Richard Goldberg, MD, talks patient response with the combination of MEK and PD-1 inhibitors

video-image

Richard M. Goldberg, MD, FASCO on the importance of the NETTER-1 study

video-image

Richard M. Goldberg, MD, discusses the gastric cancer treatment algorithm based on the CRITICS study

video-image

Richard M. Goldberg, MD, FASCO on adjuvant pancreatic cancer news

video-image

Richard Goldberg, MD, discusses selecting the right therapeutic approach for CRC patients

video-image

Richard M. Goldberg, MD, FASCO on KRAS wild type or mutant in right or left-sided mCRC patients

video-image

Richard M. Goldberg, MD, FASCO on regimen preference in mCRC 1st line treatment

video-image

Richard M. Goldberg, MD, FASCO discusses outcomes of the phase 3 CALGB/SWOG 80405 study

video-image

Bert O'Neil, MD on integrating regorafenib and trifluridine into later lines of mCRC treatment

video-image

Bert O'Neil, MD and the combination of ipilimumab with nivolumab in mCRC patients

video-image

Bert O'Neil, MD on the importance of choosing mCRC treatment based on primary tumor site

video-image

Barbara Burtness, MD on evidence for incorporating checkpoint inhibitors into treatment

video-image

Alexander Lesokhin, MD discusses the development of immunotherapies for multiple myeloma patients

video-image

Alexander Lesokhin, MD on the use of daratumumab to treat multiple myeloma patients

video-image

Alexander Lesokhin, MD provides an update on the CASTOR trial presented at ASCO 2016

video-image

Alexander Lesokhin, MD talks about the pros/cons of an all-oral regimen in the treatment of MM

video-image

Alexander Lesokhin, MD on sequencing therapies in relapsed multiple myeloma patients

video-image

Alexander Lesokhin, MD explains therapy combinations for newly diagnosed multiple myeloma patients

video-image

Alexander Lesokhin, MD talks about newly diagnosed multiple myeloma patients

video-image

Alan Venook, MD discusses development of immunotherapies for non MSI-High CRC patients

video-image

Alan Venook, MD, balancing economics with the efficacy outcomes seen in 80405

video-image

Alan Venook, MD relays the optimal dose for regorafenib (Stivarga) in the 2nd line treatment of mCRC

video-image

Alan Venook, MD on integrating regorafenib and trifluridine into the 2nd line treatment of mCRC

video-image

Alan Venook, MD on reliability of MSI-High predictor fpr response to nivolumab (Opdivo) in mCRC

video-image

Alan Venook, MD relates data presented in EPIC study relates to CALGB/SWOG 80405